Genscript BiotechGNNSF 66 Altman Z-Score is 2.98 as of Jul. 04, 2026, which is 39% below its 10-year median of 4.91. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Genscript Biotech ranks better than 52.64% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.08 is strong.
Genscript Biotech has a Altman Z-Score of 2.98, indicating it is in Grey Zones. This implies that Genscript Biotech is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Genscript Biotech's Altman Z-Score or its related term are showing as below:
GNNSF'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.36 Med: 4.91 Max: 13.17
Current: 3.08
During the past 12 years, Genscript Biotech's highest Altman Z-Score was 13.17. The lowest was 2.36. And the median was 4.91.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Genscript Biotech Altman Z-Score Related Terms
Genscript Biotech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Genscript Biotech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Genscript Biotech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0739
+
1.4
*
0.3745
+
3.3
*
-0.0934
+
0.6
*
4.1232
+
1.0
*
0.1977
=
2.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Genscript Biotech (GNNSF) has a Altman Z-Score of 2.98 as of Jul. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Genscript Biotech and its competitors. This is 39% below median its historical median of 4.91. Over the past decade, Genscript Biotech's Altman Z-Score has ranged from 2.36 to 13.17. According to the industry distribution chart, Genscript Biotech ranks #440 out of 929 companies in the Biotechnology industry, placing it in the top 47.4%.
Is Genscript Biotech's Altman Z-Score too high?
Genscript Biotech's current Altman Z-Score of 2.98 is 39% below median its 10-year median of 4.91. Over the past 10 years, this metric has ranged from a low of 2.36 to a high of 13.17. The Biotechnology industry median Altman Z-Score is 2.61. Genscript Biotech's value of 2.98 is 14.2% above this industry median. Based on the distribution chart, Genscript Biotech ranks #440 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #440 out of 929 companies for Altman Z-Score. This puts Genscript Biotech in the upper half of its industry. The industry median Altman Z-Score is 2.61. Genscript Biotech's value of 2.98 is 14.2% above this benchmark. Historically, Genscript Biotech's own Altman Z-Score has ranged from 2.36 to 13.17 over the past decade. While the company's 10-year median is 4.91 vs. the industry median of 2.61, Genscript Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Altman Z-Score of 2.98 is 14.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Altman Z-Score is 2.98, which is 39% below median its own 10-year median of 4.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Altman Z-Score is 2.98, which is 39% below median its 10-year median of 4.91 and 14.2% above the Biotechnology industry median of 2.61. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Altman Z-Score is 2.98 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Altman Z-Score: 2.98 (39% below median its 10-year median of 4.91)
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 14.2% above the Biotechnology median (#440 of 929)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
